Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The NIH sitewide notice about its website transition and use of “Super Intelligence” terminology is no longer displayed.
    Difference
    1%
    Check dated 2026-11-10T14:49:51.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-03T15:51:49.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    An NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T16:58:09.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T18:07:49.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record, with the 403 message shown near the top and site footer visible.
    Difference
    20%
    Check dated 2026-09-22T21:44:46.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    UI text for the contact information label is updated in capitalization, and a new Revision: v3.7.0 tag appears on the page.
    Difference
    0.1%
    Check dated 2026-09-15T21:55:53.000Z thumbnail image

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.